Arvinas


Biotechnology company focused on discovery and development of targeted protein degraders (PROTACs) for oncology and neurology. Maintains an integrated discovery engine combining medicinal chemistry, structural biology, proteomics, AI/ML, and preclinical/clinical development. Has advanced multiple oral and brain-penetrant degraders into clinical trials and contributed to the first FDA approval of a PROTAC therapy.

Industries

Biotechnology
Health Care
Pharmaceutical
Therapeutics
Pharmaceutical and biotechnology
Biotechnology Research

Nr. of Employees

large (251-1000)

Arvinas

New Haven, Connecticut, United States


Patents

Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides

US-12036209-B2

View Details

Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides

US-11065231-B2

View Details

Products

VEPPANU (vepdegestrant)

An orally administered estrogen receptor degrader approved in the U.S. for a specified advanced or metastatic ER+/HER2- breast cancer population, developed using targeted protein degradation approaches.

ARV-102 (LRRK2 degrader)

Investigational orally bioavailable, brain-penetrant PROTAC designed to degrade LRRK2 for neurodegenerative diseases; evaluated in Phase 1/1b studies for Parkinson’s disease and related indications.

ARV-027 (polyQ-AR degrader)

Investigational oral, peripherally restricted PROTAC intended to selectively degrade polyglutamine-expanded androgen receptor in skeletal muscle for spinal-bulbar muscular atrophy; evaluated in Phase 1/1b studies.

ARV-393 (BCL6 degrader)

Investigational orally bioavailable PROTAC designed to degrade BCL6 for B-cell lymphomas; evaluated as monotherapy and in combination in Phase 1 trials.

ARV-6723 (HPK1 degrader)

Investigational oral PROTAC targeting HPK1 to modulate immune signaling in solid tumors; evaluated in Phase 1/2 studies as monotherapy and in combination with immune checkpoint inhibitors.

ARV-806 (KRAS G12D degrader)

Investigational PROTAC designed to selectively degrade mutant KRAS G12D in solid tumors; evaluated in Phase 1/2 dose-escalation clinical trial.

Expertise Areas

  • Targeted protein degradation drug discovery
  • Medicinal chemistry for oral and CNS-penetrant small molecules
  • Structural biology and computational modeling
  • Proteomics-driven selectivity assessment
  • Show More (5)

Key Technologies

  • PROTAC targeted protein degradation
  • DNA-encoded library (DEL) screening
  • Structural modeling of ternary complexes
  • AI/ML multiparametric predictive models
  • Show More (6)

News & Updates

A research award recognizing innovation in targeted protein degradation with a $25,000 monetary prize; applications open Nov 1, 2026 and close Dec 31, 2026.

Peer-reviewed publication reporting Phase I/II clinical data for a PROTAC androgen receptor degrader in metastatic castration-resistant prostate cancer.

Publication reporting clinical data for an orally bioavailable PROTAC estrogen receptor degrader in advanced breast cancer.

Process development publication describing establishment of a commercial manufacturing route for an orally bioavailable PROTAC estrogen receptor degrader.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.